Skip to main content
SpringerLink
Log in
Book cover

Rheumaderm pp 289–293Cite as

Enalapril (10 Mg/Day) in Systemic Sclerosis

One Year, Double Blind, Randomised Study (ESS-1): Pulmonary Substudy—Effects of Three Month Treatment

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 455))

Abstract

The ESS-1 study is designed to evaluate the long-term effects of enalapril on cardiopulmonary system of patients with systemic sclerosis (SSc). During the one year study period 5 visits are scheduled at 3 month intervals. The effect of 3 months treatment with enalapril (10 mg per day) on lung function was studied in 18 patients with SSc (enalapril group) and compared with controls—23 patients with Ssc (placebo group), mean age, SSc duration, gender and % of patients with dcSSc did not differ significantly in both groups. We performed body plethysmography for total airways resistance (Rtot), and static lung volumes (TLC, ITGV and RV), spirometry for FEV, and FVC and we measured flow parameters (PEF, FEF). We compared initial lung function (first examination) with results after 3 months treatment (second examination) in the enalapril and in the placebo group. Mean values of Rtot, ITGV and RV did not differ significantly in the enalapril group or in the placebo group before and after treatment but FVC, FEV1 and FEF50 were significantly lower in the enalapril group and did not change in the placebo group after three months. We conclude that 3 month treatment with enalapril worsens spirometry of SSc patients. We did not observe any changes in lung functions in the control group in the same three month period.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Clop CR, Riker J, Wiliams MH. Serial changes in scleroderma and idiopathic interstitial lung disease. Arch Intern Med. 132: 506–515 (1973).

    Article  Google Scholar 

  2. Medsger TA jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic asclerosis (scleroderma) A life table analysis of clinical and demographic factors in 309 patients. Ann Intern Med, 75: 369–376(1971)

    PubMed  Google Scholar 

  3. Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zukner. Heart disease in systemic Sclerosis. Semin Arthritis Rheum 19: 191–200(1989).

    Article  PubMed  CAS  Google Scholar 

  4. Subcommittee for scleroderma of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23:581–590 (1980)

    Article  Google Scholar 

  5. Quanjer PH. Tammeling GJ. Cotes JE. Pedersen OF. Peslin R. Yernault JC. Volumes pulmonaires et debits ventilatoires forces. Groupe de travail sur la standardisation des epreuves fonctionnelles respiratoires. Communaute Europeenne du Charbon et de l’Acier. Position officielle de l’European Respiratory Society. Revue des Maladies Respiratoires. 11 Suppl 3:5–40 (1994).

    Google Scholar 

  6. Ulmer WT, Reichel G, Nolte D. Die Lungfunction. Physiologie. Methodik. G. Thieme Verlag. Stuttgard. 1976

    Google Scholar 

  7. Silver RM. Interstitial lung disease of systemic sclerosis. International Review of Immunology. 12: 281–291 (1995)

    Article  CAS  Google Scholar 

  8. Kane GC, Varga J, Connant EF, Spirn PW, Jimenez S, Fish JE. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respiratory medicine. 90: 223–30 (1996).

    Article  PubMed  CAS  Google Scholar 

  9. Jacobsen S, Halberg P, Ullman S, Hoier-Madsen M, Petersen J, Mortensen J, Wiik A. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin.Rheumatol. 16: 384–390 (1997).

    Article  PubMed  CAS  Google Scholar 

  10. Schneider PD, Wiese RA, Hochberg MC, Wigley FM: Serial pulmonary Function in Systemic Sclerosis. Am. J.Med. 73: 385–394 (1982).

    Article  PubMed  CAS  Google Scholar 

  11. Guttadauria M, Ellman H, Emmanuel G, Kaplan D, Diamond H. Pulmonary function in scleroderma. Arthritis Rheum. 20: 1971–1979 (1997).

    Google Scholar 

  12. Spagnolatti L, Zoia MC, Volpini E, Convertino G, Fulgoni P, Corsico A, Vitulo P, Cerveri I. Pulmonary function in patients with systemic sclerosis. Monaldi Arch. Chest Dis. 52: 4–8. (1997)

    PubMed  CAS  Google Scholar 

  13. Lofdahl CG. Antihypertensive drugs and airway function, with special reference to calcium channel blockade. J. Cardiovas. Pharmacol 14 Suppl 10: S40–51 (1989)

    Google Scholar 

  14. Pelouch V, Kolar F, Ostdal B, Milerova M, Cihak R, Widimsky J: Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: effect of enalapril. Cardiovascular Drugs and Therapy. 11(2); 177–185 (1997).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I Department of Medicine, Lublin University School of Medicine, Lublin, Poland

    St. Ostrowski MD, PhD, A. Bilan, R. Palusiński, J. Węglarz, B. Makaruk & J. Hanzlik

  2. Department of Dermatology, Lublin University School of Medicine, Lublin, Poland

    M. Chibowska & D. Krasowska

Authors
  1. St. Ostrowski MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Chibowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Bilan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Palusiński
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Węglarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Makaruk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Krasowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Hanzlik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to St. Ostrowski MD, PhD .

Editor information

Editors and Affiliations

  1. St. Luke’s Hospital, University of Malta Medical School, Malta, USA

    Carmel Mallia

  2. Jefferson Medical College, Thomas Jefferson Universit, Philadelphia, Pennsylvania, USA

    Jouni Uitto

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ostrowski, S. et al. (1999). Enalapril (10 Mg/Day) in Systemic Sclerosis. In: Mallia, C., Uitto, J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4857-7_42

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4857-7_42

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7203-5

  • Online ISBN: 978-1-4615-4857-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation